A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days af
- PDF / 1,826,339 Bytes
- 11 Pages / 610 x 792 pts Page_size
- 19 Downloads / 126 Views
Open Access
Research
A pilot study to assess the feasibility of evaluation of markers of response to chemotherapy at one day & 21 days after first cycle of chemotherapy in carcinoma of breast: a prospective non-randomized observational study Shekhar Sharma*1, KR Hiran2, K Pavithran3 and DK Vijaykumar1 Address: 1Department of Surgical Oncology, Amrita Institute of Medical Sciences & Research Center, Amrita Lane, Edapally, Ernakulam – 682026, Kerala, India, 2Department of Pathology, Amrita Institute of Medical Sciences & Research Center, Amrita Lane, Edapally, Ernakulam – 682026, Kerala, India and 3Department of Medical Oncology, Amrita Institute of Medical Sciences & Research Center, Amrita Lane, Edapally, Ernakulam – 682026, Kerala, India Email: Shekhar Sharma* - [email protected]; KR Hiran - [email protected]; K Pavithran - [email protected]; DK Vijaykumar - [email protected] * Corresponding author
Published: 30 March 2009 World Journal of Surgical Oncology 2009, 7:35
doi:10.1186/1477-7819-7-35
Received: 10 December 2008 Accepted: 30 March 2009
This article is available from: http://www.wjso.com/content/7/1/35 © 2009 Sharma et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background: Interest in translational studies aimed at investigating biologic markers in predicting response to primary chemotherapy (PCT) in breast cancer has progressively increased. We conducted a pilot study to evaluate feasibility of evaluating biomarkers of response to PCT at one & 21 days after first cycle. Methods: Adult, non-pregnant, non-lactating women with histologically confirmed infiltrating duct carcinoma underwent serial core biopsies after first cycle of PCT and these were scored for Ki-67, Bcl-2 and Caspase-3 using immunohistochemistry. Results: We recruited 30 patients with a mean age of 51 years. We were successful 95.6% times in performing a core biopsy and of these 84.6% had adequate tissue in the cores harvested. After a mean of 4 cycles of PCT, 26 patients underwent surgery and good response was noted in 9 patients (30%) using Miller-Payne criteria. There was a trend noted in all markers, which appeared different in those with good response and poor response. Good responders had significantly higher Ki-67 and significantly lower Bcl-2 at baseline and a significant decrease in Ki-67 and Caspase-3 at 21 days after the first chemotherapy. Conclusion: We report a detectable change in biomarkers as early as 24–48 hours after the first chemotherapy along with a definite trend in change that can possibly be used to predict response to chemotherapy in an individual patient. The statistical significance and clinical utility of such changes needs to be evaluated and confirmed in larger trials.
Background There is increasing int
Data Loading...
